Factors contributing to tumor shrinkage after peptide receptor radionuclide therapy in patients with unresectable neuroendocrine tumors

#3668

Introduction: Peptide receptor activation therapy (PRRT) is a promising treatment option for metastatic neuroendocrine tumors (NETs). However, predicting tumor shrinkage before treatment is challenging.

Aim(s): We analysed the shrinkage rate of each metastatic tumor lesion to identify predictive factors related to shrinkage.

Materials and methods: Patients with metastatic NET who underwent PRRT at the Basel University Hospital were included in this retrospective study. 1–5 lesions were evaluated per patient. For each patient, the change in the maximum tumor diameter after treatment was defined as the shrinkage rate per lesion (L-SR). We analysed the relationship between pre-treatment clinicopathological factors and L-SR.

Conference:

Presenting Author:

Authors: Noritoshi K, Sho H, Wild D, Kaul F, Motokazu S,

Keywords: lesion-based analysis, neuroendocrine tumor, peptide receptor radionuclide therapy,